Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile

Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME2456D
  • |
  • Pages: 153
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company's sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 8

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 12

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13

Qiagen NV, Medical Equipment, Deal Details 18

Asset Purchase 18

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18

Venture Financing 19

ArcherDX Raises USD35 Million in Series A Financing 19

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20

Protagen Raises USD12.5 Million in Venture Financing 22

Curetis Raises USD18 Million in Extended Series B Venture Financing 23

Exosome Diagnostics Raises USD 27 Million In Series B Financing Round 25

Drug Response Dx Raises Funds Through First Round Of Venture Financing 27

Xagenic Raises USD 10 Million In Series A Venture Financing 28

Partnerships 29

Qiagen Enters into Licensing Agreement with Johns Hopkins University 29

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30

Qiagen Enters into Licensing Agreement with MDxHealth 31

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40

Merck and ArcherDX Enter into Co-Development Agreement 41

QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42

Qiagen Enters into Partnership with Freenome 43

QIAGEN Enters into Agreement with Natera 44

Biomillenia Enters into Agreement with Qiagen 45

Qiagen and Centogene Enter into Co-Marketing Agreement 46

ANGLE Enters into Co-Marketing Agreement with Qiagen 47

DiaSorin Enters into Agreement with QIAGEN 48

Qiagen Forms Joint Venture with Maccura Biotech 49

ArcherDX and HeliTec Enter into Partnership 50

Singulex Enters into Agreement with Qiagen 51

Sophia Genetics Enters into Agreement with Qiagen 52

Sophia Genetics Enters into Agreement with ArcherDx 53

SeraCare Life Sciences Enters into Agreement with ArcherDx 54

Qiagen Enters into Agreement with Genohm 55

ArcherDx Enters into Partnership with PierianDx 56

ArcherDX Enters into Co-Development Agreement with Illumina 57

CareDx to Partner with Qiagen 58

Qiagen Enters into Partnership with Therawis Diagnostics 59

CosmosID Enters into Agreement with Qiagen 60

NanoString Technologies Enters into Co-Development Agreement with HalioDx 61

Qiagen Enters into Agreement with 10X Genomics 62

Qiagen Enters into Co-Development Agreement with Array BioPharma 63

ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64

Qiagen Forms Joint Venture with Biotype Diagnostics 65

Qiagen Enters into Agreement with Hitachi High-Technologies 66

Qiagen Enters into Agreement with GATC Biotech 67

Tokai Pharma Expands Agreement with Qiagen 68

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70

Qiagen Enters into Co-Development Agreement with Novartis 71

Qiagen Enters into Co-Development Agreement with Astellas Pharma 72

AstraZeneca Enters into Co-Development Agreement with Qiagen 73

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86

Qiagen Enters Into Co-Development Agreement With Eli Lilly 87

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96

Inserm Transfert Enters into Licensing Agreement with HalioDx 97

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98

Transgenomic Expands Licensing Agreement with Exiqon 99

Equity Offering 100

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 100

Debt Offering 101

Qiagen Raises USD400 Million in Private Placement of Notes 101

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 103

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 104

Exiqon Completes Private Placement Of Bonds For USD 3 Million 105

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108

Asset Transactions 109

Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110

Acquisition 111

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111

Qiagen Acquires STAT-Dx 112

Qiagen Acquires OmicSoft 113

Qiagen Acquires Exiqon for up to USD102.4 Million 114

Qiagen Acquires MO BIO Labs 116

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117

Qiagen Acquires CLC bio 118

Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For USD 50 Million 119

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120

Qiagen NV-Key Competitors 121

Qiagen NV-Key Employees 122

Qiagen NV-Locations And Subsidiaries 123

Head Office 123

Other Locations & Subsidiaries 123

Joint Venture 126

Recent Developments 127

Financial Announcements 127

Jul 31, 2018: QIAGEN Reports Results for Second Quarter and First Half of 2018 127

May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 130

Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 132

Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 137

May 02, 2017: QIAGEN reports results for first quarter 2017 140

Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 142

Government and Public Interest 145

Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 145

Product News 146

Nov 15, 2017: QIAGEN advances precision medicine by automating guidelines on cancer variants in industry-leading QIAGEN Clinical Insight software 146

Apr 03, 2017: QIAGENs GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 147

Other Significant Developments 148

Sep 27, 2018: HTG Molecular announces extension to precision diagnostic partnership PDP program three for companion diagnostic submission 148

Aug 01, 2018: QIAGEN creates collaboration with Japans largest clinical laboratory testing company, SRL, to accelerate launch of companion diagnostics 149

Feb 07, 2018: QIAGEN and Sentieon Partner to Advance Precision Medicine With Highly Efficient Variant-Calling Software 150

Jan 08, 2018: QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements 151

Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 152

Appendix 153

Methodology 153

About GlobalData 153

Contact Us 153

Disclaimer 153

List of Figures

Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 12

List of Tables

Qiagen NV, Medical Equipment, Key Facts, 2017 2

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Deals By Market, 2012 to YTD 2018 12

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18

ArcherDX Raises USD35 Million in Series A Financing 19

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20

Protagen Raises USD12.5 Million in Venture Financing 22

Curetis Raises USD18 Million in Extended Series B Venture Financing 23

Exosome Diagnostics Raises USD 27 Million In Series B Financing Round 25

Drug Response Dx Raises Funds Through First Round Of Venture Financing 27

Xagenic Raises USD 10 Million In Series A Venture Financing 28

Qiagen Enters into Licensing Agreement with Johns Hopkins University 29

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30

Qiagen Enters into Licensing Agreement with MDxHealth 31

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40

Merck and ArcherDX Enter into Co-Development Agreement 41

QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42

Qiagen Enters into Partnership with Freenome 43

QIAGEN Enters into Agreement with Natera 44

Biomillenia Enters into Agreement with Qiagen 45

Qiagen and Centogene Enter into Co-Marketing Agreement 46

ANGLE Enters into Co-Marketing Agreement with Qiagen 47

DiaSorin Enters into Agreement with QIAGEN 48

Qiagen Forms Joint Venture with Maccura Biotech 49

ArcherDX and HeliTec Enter into Partnership 50

Singulex Enters into Agreement with Qiagen 51

Sophia Genetics Enters into Agreement with Qiagen 52

Sophia Genetics Enters into Agreement with ArcherDx 53

SeraCare Life Sciences Enters into Agreement with ArcherDx 54

Qiagen Enters into Agreement with Genohm 55

ArcherDx Enters into Partnership with PierianDx 56

ArcherDX Enters into Co-Development Agreement with Illumina 57

CareDx to Partner with Qiagen 58

Qiagen Enters into Partnership with Therawis Diagnostics 59

CosmosID Enters into Agreement with Qiagen 60

NanoString Technologies Enters into Co-Development Agreement with HalioDx 61

Qiagen Enters into Agreement with 10X Genomics 62

Qiagen Enters into Co-Development Agreement with Array BioPharma 63

ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64

Qiagen Forms Joint Venture with Biotype Diagnostics 65

Qiagen Enters into Agreement with Hitachi High-Technologies 66

Qiagen Enters into Agreement with GATC Biotech 67

Tokai Pharma Expands Agreement with Qiagen 68

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70

Qiagen Enters into Co-Development Agreement with Novartis 71

Qiagen Enters into Co-Development Agreement with Astellas Pharma 72

AstraZeneca Enters into Co-Development Agreement with Qiagen 73

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86

Qiagen Enters Into Co-Development Agreement With Eli Lilly 87

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96

Inserm Transfert Enters into Licensing Agreement with HalioDx 97

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98

Transgenomic Expands Licensing Agreement with Exiqon 99

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 100

Qiagen Raises USD400 Million in Private Placement of Notes 101

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 103

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 104

Exiqon Completes Private Placement Of Bonds For USD 3 Million 105

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108

Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110

QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111

Qiagen Acquires STAT-Dx 112

Qiagen Acquires OmicSoft 113

Qiagen Acquires Exiqon for up to USD102.4 Million 114

Qiagen Acquires MO BIO Labs 116

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117

Qiagen Acquires CLC bio 118

Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For USD 50 Million 119

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120

Qiagen NV, Key Competitors 121

Qiagen NV, Key Employees 122

Qiagen NV, Subsidiaries 123

Qiagen NV, Joint Venture 126

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Qiagen NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18103
Site License
USD 500 INR 36205
Corporate User License
USD 750 INR 54308

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com